Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
Department of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.01800-18. Print 2019 Apr.
Vancomycin-resistant (VRE) is a leading cause of hospital-acquired infection, with limited treatment options. Resistance to one of the few remaining drugs, daptomycin, is a growing clinical problem and has previously been described in this hospital. In response to increasing resistance, an antimicrobial stewardship intervention was implemented to reduce hospital-wide use of daptomycin. To assess the impact of the intervention, daptomycin prescribing patterns and clinically reported culture results from vancomycin-resistant (VREfm) bloodstream infections (BSIs) from 2011 through 2017 were retrospectively extracted and the impact of the intervention was estimated using interrupted time series analysis (ITS). We corrected for a change in MIC determination methodology by retesting 262 isolates using Etest and broth microdilution. Hospital-wide and within-patient resistance patterns of corrected daptomycin MICs are reported. Our data show that daptomycin prescriptions decreased from an average of 287 days of therapy/month preintervention to 151 days of therapy/month postintervention. Concurrently, the proportion of patients experiencing an increase in daptomycin MIC during an infection declined from 14.6% (7/48 patients) in 2014 to 1.9% (1/54 patients) in 2017. Hospital-wide resistance to daptomycin also decreased in the postintervention period, but this was not maintained. This study shows that an antimicrobial stewardship-guided intervention reduced daptomycin use and improved individual level outcomes but had only transient impact on the hospital-level trend.
耐万古霉素肠球菌(VRE)是医院获得性感染的主要原因,其治疗选择有限。对为数不多的几种剩余药物之一达托霉素的耐药性是一个日益严重的临床问题,以前在本医院已有描述。为了应对耐药性的增加,实施了抗菌药物管理干预措施,以减少达托霉素在全院的使用。为了评估干预措施的影响,我们回顾性地提取了 2011 年至 2017 年耐万古霉素肠球菌(VREfm)血流感染(BSI)的达托霉素处方模式和临床报告的培养结果,并使用中断时间序列分析(ITS)来估计干预措施的影响。我们通过使用 Etest 和肉汤微量稀释法重新测试 262 株分离株来纠正 MIC 测定方法的变化。报告了校正后达托霉素 MIC 的全医院和患者内耐药模式。我们的数据表明,达托霉素的处方量从干预前平均每月 287 天的治疗量减少到干预后每月 151 天的治疗量。同时,在感染过程中达托霉素 MIC 增加的患者比例从 2014 年的 14.6%(48 例患者中的 7 例)下降到 2017 年的 1.9%(54 例患者中的 1 例)。干预后全医院对达托霉素的耐药性也有所下降,但这种情况并未持续。这项研究表明,抗菌药物管理指导的干预措施减少了达托霉素的使用并改善了个体水平的结果,但对医院层面的趋势仅产生了短暂的影响。